Ultra-long acting oral dosage forms have been a goal for the pharma industry for years given that fewer repeat doses would improve patient compliance. But the developmental hurdles are manifold – the system has to stay stable in a capsule form for years, rapidly deploy in the gastric cavity, achieve multi-day gastric residence, release the drug in a linear fashion, and then exit safely out of the gastrointestinal tract. Not easy. But Researchers at MIT and Brigham and Women’s Hospital think they have mitigated these problems and developed a drug delivery system capable of safely residing in the stomach for two weeks. We asked Giovanni Traverso, senior author of the paper, and a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, to tell us more.

Read the full article now Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be! Login Email Password Forgot your password? Keep me logged in Log in Or register now - it’s free and always will be! You will benefit from: Unlimited access to ALL articles

News, interviews & opinions from leading industry experts

Receive print (and PDF) copies of The Medicine Maker magazine Register Or Login via Social Media Twitter By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.



From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.